Stock Forums › Stocks Forum › Nasdaq Stocks › CELG – Celgene Corporation
Tagged: CELG, Celgene, multiple myeloma
This topic contains 5 replies, has 1 voice, and was last updated by Stocks News Feed 2 months ago.
CELG – Celgene Receives European Commission Approvals for REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-based Triplet Combination Regimens for Patients with Multiple Myeloma
CELG – Celgene Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis
CELG: Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) announced the FDA has accepted its New Drug Application (NDA) for fedratinib for the treatment of patients with myelofibrosis and granted a priority review. The PDUFA date is September 3, 2019.
Done Reading? You might also find these links useful:
Stock Market News | Social Activity Stream | Stock Forums
Enter your email address to subscribe to StocksNewsFeed newsletter and receive notifications by email.